SAN ANTONIO--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today presented data in an oral presentation at the 29th Annual San Antonio Breast Cancer Symposium (SABCS) from an interim analysis of a randomized, head-to-head Phase II trial of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) versus Taxotere® (docetaxel) Injection Concentrate, in the first-line treatment of metastatic breast cancer. The interim analysis showed that first-line treatment with weekly ABRAXANE (100 and 150 mg/m2) increased tumor response rate by greater than 60 percent with less toxicity versus Taxotere (100 mg/m2) given every three weeks in patients with metastatic breast cancer. The interim analysis also showed that weekly ABRAXANE nearly doubled the response rate with less toxicity compared to ABRAXANE (300 mg/m2) dosed every three weeks. Although the data are not fully mature, the interim analysis showed that all three ABRAXANE regimens currently have longer progression-free survivals than Taxotere dosed every three weeks. A blinded, independent radiological review of the response data is in process and the company intends to submit the final analysis of the data to the American Society of Clinical Oncology (ASCO) in 2007.
